piR-651 and its function in 95-D lung cancer cells

Yao,Jie; Wang,Yu Wen; Fang,Biao Biao; Zhang,Shu Jun; Cheng,Bing Lin

doi:10.3892/br.2016.628

piR-651 and its function in 95-D lung cancer cells

Authors:
- Jie Yao
- Yu Wen Wang
- Biao Biao Fang
- Shu Jun Zhang
- Bing Lin Cheng
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150000, P.R. China, Department of Pathology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150000, P.R. China
Published online on: March 8, 2016 https://doi.org/10.3892/br.2016.628
Pages: 546-550
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

PIWI-associated RNAs (piRNAs or piRs), a new-found class of small non-coding RNAs, which are mainly expressed in germline cells and partly in somatic lines, have a vital role in carcinogenesis by maintaining genomic integrity and regulation of epigenetics. The previous studies have confirmed that the expression of piR‑651 is upregulated in several cancer tissue and cell lines, including lung cancer. However, the mechanism of carcinogenesis and piR‑651 remains to be elucidated. Therefore, the present study assessed the 95‑D high metastasis human lung cancer cell line to detect the effect of piR‑651 on carcinogenesis. Firstly, piR‑651 promoted the high metastasis characteristic of the 95‑D cell lines by Transwell and wound‑healing assays. The influence of piR‑651 on tumor cell proliferation and apoptosis was detected by the MTT assay and flow cytometry. In conclusion, piR-651 may be an oncogene in lung cancer formation and development. Therefore, piR-651 regulated carcinogenesis by influencing cell proliferation, apoptosis, migration and invasion, and may be a potential tumor marker and therapeutic target.

View Figures

View References

1	WHO International Agency for Research on Cancer (IARC): Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. WHO. Geneva: 2012.
2	Chen B, Zhang B, Xia L, Zhang J, Chen Y, Hu Q and Zhu C: Knockdown of eukaryotic translation initiation factor 4E suppresses cell growth and invasion, and induces apoptosis and cell cycle arrest in a human lung adenocarcinoma cell line. Mol Med Rep. 12:7971–7978. 2015.PubMed/NCBI
3	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
4	Sun Y, Ai X, Shen S and Lu S: NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. Oncotarget. 2:1–11. 2015.
5	Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al: International Human Genome Sequencing Consortium: Initial sequencing and analysis of the human genome. Nature. 409:860–921. 2001. View Article : Google Scholar : PubMed/NCBI
6	Ohno S: So much ‘junk’ DNA in our genome. Brookhaven Symp Biol. 23:366–370. 1972.PubMed/NCBI
7	Peters L and Meister G: Argonaute proteins: Mediators of RNA silencing. Mol Cell. 26:611–623. 2007. View Article : Google Scholar : PubMed/NCBI
8	Hutvagner G and Simard MJ: Argonaute proteins: Key players in RNA silencing. Nat Rev Mol Cell Biol. 9:22–32. 2008. View Article : Google Scholar : PubMed/NCBI
9	Siomi MC, Sato K, Pezic D and Aravin AA: PIWI-interacting small RNAs: The vanguard of genome defence. Nat Rev Mol Cell Biol. 12:246–258. 2011. View Article : Google Scholar : PubMed/NCBI
10	Zhang B, Pan X, Cobb GP and Anderson TA: MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
11	Dieckmann KP, Spiekermann M, Balks T, Flor I, Löning T, Bullerdiek J and Belge G: MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer. 107:1754–1760. 2012. View Article : Google Scholar : PubMed/NCBI
12	Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A, Boland CR and Goel A: The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One. 7:e466842012. View Article : Google Scholar : PubMed/NCBI
13	Aravin A, Gaidatzis D, Pfeffer S, Lagos-Quintana M, Landgraf P, Iovino N, Morris P, Brownstein MJ, Kuramochi-Miyagawa S, Nakano T, et al: A novel class of small RNAs bind to MILI protein in mouse testes. Nature. 442:203–207. 2006.PubMed/NCBI
14	Girard A, Sachidanandam R, Hannon GJ and Carmell MA: A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature. 442:199–202. 2006.PubMed/NCBI
15	Grivna ST, Beyret E, Wang Z and Lin H: A novel class of small RNAs in mouse spermatogenic cells. Genes Dev. 20:1709–1714. 2006. View Article : Google Scholar : PubMed/NCBI
16	Lu Y, Li C, Zhang K, Sun H, Tao D, Liu Y, Zhang S and Ma Y: Identification of piRNAs in Hela cells by massive parallel sequencing. BMB Rep. 43:635–641. 2010. View Article : Google Scholar : PubMed/NCBI
17	Cheng J, Deng H, Xiao B, Zhou H, Zhou F, Shen Z and Guo J: piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells. Cancer Lett. 315:12–17. 2012. View Article : Google Scholar : PubMed/NCBI
18	Cheng J, Guo JM, Xiao BX, Miao Y, Jiang Z, Zhou H and Li QN: piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells. Clin Chim Acta. 412:1621–1625. 2011. View Article : Google Scholar : PubMed/NCBI
19	Zhang H, Ren Y, Xu H, Pang D, Duan C and Liu C: The expression of stem cell protein Piwil2 and piR-932 in breast cancer. Surg Oncol. 22:217–223. 2013. View Article : Google Scholar : PubMed/NCBI
20	Huang G, Hu H, Xue X, Shen S, Gao E, Guo G, Shen X and Zhang X: Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer. Clin Transl Oncol. 15:563–568. 2013. View Article : Google Scholar : PubMed/NCBI
21	Chu H, Hui G, Yuan L, Shi D, Wang Y, Du M, Zhong D, Ma L, Tong N, Qin C, et al: Identification of novel piRNAs in bladder cancer. Cancer Lett. 356(2 Pt B): 561–567. 2015. View Article : Google Scholar : PubMed/NCBI
22	Law PT, Qin H, Ching AK, Lai KP, Co NN, He M, Lung RW, Chan AW, Chan TF and Wong N: Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. J Hepatol. 58:1165–1173. 2013. View Article : Google Scholar : PubMed/NCBI
23	Liu X, Yan S, Pei C and Cui Y: Decreased microRNA-132 and its function in human non-small cell lung cancer. Mol Med Rep. 11:3601–3608. 2015.PubMed/NCBI
24	Grimson A, Srivastava M, Fahey B, Woodcroft BJ, Chiang HR, King N, Degnan BM, Rokhsar DS and Bartel DP: Early origins and evolution of microRNAs and Piwi-interacting RNAs in animals. Nature. 455:1193–1197. 2008. View Article : Google Scholar : PubMed/NCBI
25	Meister G: Argonaute proteins: Functional insights and emerging roles. Nat Rev Genet. 14:447–459. 2013. View Article : Google Scholar : PubMed/NCBI
26	Siddiqi S and Matushansky I: Piwis and piwi-interacting RNAs in the epigenetics of cancer. J Cell Biochem. 113:373–380. 2012. View Article : Google Scholar : PubMed/NCBI
27	Cryns V and Yuan J: Proteases to die for. Genes Dev. 12:1551–1570. 1998. View Article : Google Scholar : PubMed/NCBI
28	Huang F, Huang M, Zhang H, Zhang C, Zhang D and Zhou G: Changes in apoptotic factors and caspase activation pathways during the postmortem aging of beef muscle. Food Chem. 190:110–114. 2016. View Article : Google Scholar : PubMed/NCBI
29	Liu Y, Mayo MW, Xiao A, Hall EH, Amin EB, Kadota K, Adusumilli PS and Jones DR: Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1. Mol Cell Biol. 35:303–317. 2015. View Article : Google Scholar : PubMed/NCBI